INIBIOLP 05426
INSTITUTO DE INVESTIGACIONES BIOQUIMICAS DE LA PLATA "PROF. DR. RODOLFO R. BRENNER"
Unidad Ejecutora - UE
artículos
Título:
Hybrid Ofloxacin/eugenol co-loaded solid lipid nanoparticles with enhanced and targetable antimicrobial properties
Autor/es:
RODENAK-KLADNIEW, B.; DI IANNI, M.; ALVAREZ, V.A.; ISLAN, G.A.; SBARAGLINI, M.L.; TALEVI, A.; CASTRO, G.R.; SBARAGLINI, M.L.; TALEVI, A.; CASTRO, G.R.; SCIOLI MONTOTO, S.; RUIZ, M.E.; DURÁN, N.; SCIOLI MONTOTO, S.; RUIZ, M.E.; DURÁN, N.; RODENAK-KLADNIEW, B.; DI IANNI, M.; ALVAREZ, V.A.; ISLAN, G.A.
Revista:
INTERNATIONAL JOURNAL OF PHARMACEUTICS
Editorial:
ELSEVIER SCIENCE BV
Referencias:
Año: 2019 vol. 569
ISSN:
0378-5173
Resumen:
In the global context of an imminent emergence of multidrug-resistant microorganisms, the present workcombined the use of nanotechnology and the therapeutic benefits of natural compounds as a strategy to potentiate antimicrobial action of the wide-spectrum antibiotic Ofloxacin (Ofx). Hybrid solid lipid nanoparticles (SLN) were synthesized by incorporation of chitosan (Chi, a cationic biopolymer with antimicrobial activity) and eugenol (Eu, a phenolic compound that interferes with bacterial quorum sensing) into a lipid matrix by hot homogenization/ultrasonication method. The developed SLN/Chi/Eu sustainably released the encapsulated Ofx for 24 h. Characterization by DLS, TEM, DSC, TGA and XRD revealed the presence of positively charged spherical nanoparticles with diameters around 300 nm and Ofx entrapped in amorphous state. The SLN exhibited anenhanced bactericidal activity against Pseudomonas aeruginosa and Staphylococcus aureus. The minimum inhibitory concentration (MIC) for free and nanoencapsulated Ofx formulations was below 1.0 μg/ml. The MIC values decreased by 6.1- to 16.1-fold when Ofx was encapsulated in SLN/Chi/Eu. Fluorescent-labeled nanoparticles had the ability to interact with the bacterial cell membrane. Selective toxicity of SLN/Chi/Eu-Ofx was tested in the range of 0.3?30.0 μg/ml and showed no toxicity up to 3.0 μg/ml Ofx in human cell models (A549 and Wi-38) at 24 h and 48 h exposure. It was proved that the administration of hybrid SLN to mice by dry powder inhalation reached therapeutic Ofx levels in lungs.
